Drug development pipelines are infamously long, with inefficiencies in clinical trial design being a major contributor to lost and wasted time. QuantHealth sets out to change this, with an intelligent platform capable of predicting the outcomes and risks of complex clinical trials, allowing them to be optimised for safety and effectiveness before they are deployed.
With QuantHealth, drug developers can run synthetic trials before real-world ones, which allow them to discover much more quickly and easily if designs are unsafe or suboptimal. This means that the only drugs making it to real-world trials are those that are especially promising, meaning the time, money and manpower associated with trialling is not going to waste.
With the potential to make a real difference to health outcomes, QuantHealth's offering is certainly intriguing. Having raised substantial funding, the company is aiming to expand its platform for preclinical and drug discovery, as well as build out its team with commercial and operations talent.
Kirsty
Company Specialist at Welcome to the Jungle